FUSCC-PCMC breast cancer mutation

Remarkable advances in next-generation sequencing technology enable the wide usage of sequencing as a clinical tool. Here, we conducted a large-scale prospective clinical sequencing program using the Fudan-BC panel, and comprehensively analyzed the clinical and genomic characteristics for Chinese breast cancer. A total of 4,079 consecutive Chinese patients who were treated at the Department of Breast Surgery at Fudan University Shanghai Cancer Center (FUSCC) were enrolled in this cohort from April 1, 2018, to June 1, 2021. This submission included the data from June 1, 2020 to June 30, 2020.